CIRCUL Ring Pulse Oximeter in Dark-Pigmented Individuals: Clinical Study Validates Efficacy and Reliability

CIRCUL Ring Pulse Oximeter clinical study validates efficacy and reliability in dark-pigmented participants, positioning as a superior continuous blood oxygen monitoring device for minority populations in the US and globally.

The reliability of pulse oximeters, noninvasive devices for assessing heart rate and oxygen-saturated hemoglobin, have recently been critiqued following an article published in the New England Journal of Medicine that suggested Black patients were at higher risk for hypoxemia and subsequent negative health impacts due to less accurate pulse oximeter measurements relative to those of white patients.

The CIRCUL™ Ring clinical validation study, conducted at the Tongde Hospital of Zhejiang Province, China, compared simultaneous measurements for the CIRCUL™ Ring and an arterial blood gas (ABG) test from 12 individuals (4 Black, ~33% of total enrollment). ABG test results are considered to be the most accurate method for measuring blood oxygenation levels but are more invasive due to the necessity of intravenous blood sampling. For Black individuals, 100 oxygen saturation measurements from the CIRCUL™ Ring showed excellent correlation with data obtained simultaneously from ABG testing for oxygen saturations ranging from 100% to 70%. The mean difference between CIRCUL™ and ABG values was only 1.06%.

The ongoing COVID pandemic highlights the importance of monitoring individuals’ blood oxygenation (SpO2) before, during, and after exposure or infection.

This was emphasized in a January 25, 2021 letter to the US Food and Drug Administration (FDA) by Senators Elizabeth Warren (D-Mass.), Cory Booker (D-N.J.), and Ron Wyden (D-Ore.) requesting a review of the accuracy of pulse oximeters across racially diverse patients and consumers.

The letter cites several studies suggesting pulse oximeters provide less accurate measurements for Black patients when compared to white patients, likely the result of racial bias in device calibration.

One such study found that low levels of blood oxygenation were up to three times as likely to go undetected in Black patients. The authors of that study further conclude their findings “highlight an ongoing need to understand and correct racial bias in pulse oximetry and other forms of medical technology.”

1 Oversight Letter to FDA dated January 25, 2021, “Senators Warren, Booker and Wyden Urge FDA to Address Concerns about Dangerous Pulse Oximeter Inaccuracies for Patients of Color”, https://www.warren.senate.gov/oversight/letters/senators-warren-booker-and-wyden-urge-fda-to-address-concerns-about-dangerous-pulse-oximeter-inaccuracies-for-patients-of-color

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”